Blocking IKK-mediated IĸBα degradation and NF-ĸB activation, repression of NF-ĸB transactivation potential and stabilization of IĸB has been shown to inhibit aberrant gene expression, malignant phenotypes and therapeutic resistance in pre-clinical models of prostate cancer [11–14]. The gene discussed is ATP8A2; the disease is prostate cancer.